-
Valsartan
- indication:For the treatment of hypertension.
- pharmacologypharmacology:
- mechanism: Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
- toxicity:
- absorprion: Absolute bioavailability = 23% with high variability
- halflife: The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
- roouteelimination:
- volumedistribution: * 17 L
- clearance: * 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]